Ablexis Announces Expansion of Non-Exclusive Perpetual License Agreement with Eli Lilly and Company

Expanded rights enable broader use of AlivaMab Mouse™ platform

SAN DIEGO–(BUSINESS WIRE)–Ablexis,
LLC
, a biopharmaceutical company focused on licensing its AlivaMab
Mouse platform technology for antibody drug discovery, today announced
the expansion of its existing non-exclusive perpetual license agreement
with Eli Lilly and Company. The expanded rights will more broadly enable
EIi Lilly to use the AlivaMab Mouse platform for projects with
collaborators, including the right to grant sub-licenses to antibody
drug candidates much earlier in discovery. Financial terms of the
agreement include an undisclosed upfront payment from Eli Lilly. Any
potential milestones and royalties on product sales would be paid by the
sub-licensees of the AlivaMab Mouse platform.

“This agreement further advances Ablexis’ goal of making AlivaMab Mouse
more broadly available for the discovery of the next generation of
antibody-based therapeutics,” said Larry Green, Ph.D., Chief Executive
Officer of Ablexis and AlivaMab Discovery Services, LLC. “Within the
span of just a few weeks the AlivaMab Mouse platform consistently
delivers diverse panels of high-affinity, high-potency antibodies with
favorable developability qualities and reduced chance of immunogenicity.
This represents a significant advantage over in vitro display
approaches or other transgenic animal platforms. We look forward to
continue making AlivaMab Mouse the platform of choice for experienced
antibody drug discoverers and developers.”

About Ablexis, LLC
Ablexis, LLC created and commercializes
the AlivaMab Mouse technology, a unique, patented next generation
transgenic mouse platform for human therapeutic antibody discovery.
Ablexis has non-exclusively licensed the AlivaMab Mouse technology to
multiple companies, including global pharmaceutical companies, public
and private biotechnology companies and other entities. Ablexis
continues making the AlivaMab Mouse available via non-exclusive
licenses. For more information, visit www.ablexis.com.
For inquiries about licensing AlivaMab Mouse, contact us at info@ablexis.com.

AlivaMab Discovery Services was established by Ablexis in response to
many prospective partners wanting to outsource discovery to a
scientifically-driven organization led by a team with in-the-trenches
experience and real understanding of therapeutic antibody discovery and
development. AlivaMab Discovery Services leverages the AlivaMab Mouse,
developed by Ablexis as the platform for discovery projects conducted on
behalf of clients. For more information, visit www.alivamab.com.

Contacts

Christine Quern
cq@christinequern.com
617-650-8497

Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy

CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company
focused on developing compounds that activate Tie2 to treat ocular
diseases and diabetic complications, today announced the completion of
patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial
designed to assess the efficacy and safety of Aerpio’s lead candidate,
AKB-9778, for patients with moderate to severe non-proliferative
diabetic retinopathy (NPDR).

“We are pleased to announce completion of patient dosing in our 48-week
Phase 2b trial, TIME-2b,” said Stephen Hoffman, M.D., Ph.D., Chief
Executive Officer of Aerpio. “We now expect to announce top-line results
in March 2019, earlier than our previous guidance of the second quarter
of 2019. AKB-9778 is our first-in-class, systemically-administered Tie2
activator in development for the treatment of diabetic retinopathy, as
well as complications of diabetes and other ocular diseases. The data
obtained in our TIME-2 Phase 2a study were very encouraging, not only in
demonstrating improvement in diabetic retinopathy, but also showing, in
a post-hoc analysis, improvement of kidney function. We believe
AKB-9778 has the potential to provide patients with diabetes a
significant treatment option, spanning multiple diabetic complications.”

TIME-2b Study Overview

The TIME-2b study is a double-masked, placebo-controlled, multi-center
trial evaluating the effect of AKB-9778 in 167 patients with moderate to
severe NPDR. Patients were randomized to receive 48 weeks of treatment
with either AKB-9778 15 mg subcutaneously once daily (and placebo
subcutaneously once daily), AKB-9778 15 mg subcutaneously twice daily,
or placebo subcutaneously twice daily. The primary endpoint of the
TIME-2b study is the percentage of patients who improve by 2 or more
steps in diabetic retinopathy severity score (DRSS) in the study eye.
One of the secondary objectives, the urine albumin to creatinine ratio
or UACR, was prospectively included based on a post-hoc analysis
of this biomarker in the TIME-2 Phase 2a clinical trial of AKB-9778.
Initial results from this trial are expected in March 2019.

About AKB-9778

AKB-9778 is being developed as a subcutaneous injection for the
treatment of non-proliferative diabetic retinopathy. AKB-9778 binds to
and inhibits vascular endothelial protein tyrosine phosphatase (VE-PTP),
an important negative regulator of Tie2. Decreased Tie2 activity
contributes to vascular instability in many diseases including diabetes.
AKB-9778 activates the Tie2 receptor irrespective of extracellular
levels of its binding ligands, angiopoietin-1 (agonist) or
angiopoietin-2 (antagonist) and may be the most efficient pharmacologic
approach to maintain normal Tie2 activation.

About Diabetic Retinopathy

Diabetic retinopathy (DR) is a complication of diabetes caused by damage
to blood vessels in the retina. DR occurs in roughly one of three
patients with diabetes and involves both eyes 75% of these patients.
Severity of DR ranges from mild non-proliferative diabetic retinopathy
to more advanced proliferative diabetic retinopathy, the hallmark of
which is the development of new abnormal blood vessels. DR is the
leading cause of blindness among working aged adults around the world,
affecting roughly 140 million diabetics globally.

About Aerpio Pharmaceuticals

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class compounds that activate Tie2 to treat ocular
diseases and complications of diabetes. The Company’s lead compound,
AKB-9778, is a systemically-administered small molecule activator of the
Tie2 pathway (via highly selective and potent deactivation of VE-PTP)
and is in clinical development for the treatment of non-proliferative
diabetic retinopathy. AKB-9778 is also being investigated for its
potential utility in treating diabetic nephropathy and an eyedrop
formulation is in development as a potential treatment for open-angle
glaucoma. For more information, please visit www.aerpio.com.

Contacts

Investor & Media:
Aerpio
Pharmaceuticals, Inc.

Michael Rogers
Chief Financial
Officer
mrogers@aerpio.com
or
Burns
McClellan, on behalf of Aerpio Pharmaceuticals, Inc.

Media:
Nancie
Steinberg / Robert Flamm, Ph.D.
nsteinberg@burnsmc.com
/ rflamm@burnsmc.com
or
Investors:
John
Grimaldi
jgrimaldi@burnsmc.com

LifeMap Sciences to Present Novel WGS Structural Variation Interpretation at PMWC 2019

ALAMEDA, Calif.–(BUSINESS WIRE)–LifeMap Sciences, a subsidiary of AgeX Therapeutics, Inc., announced
today that it will be presenting its novel whole genome sequencing (WGS)
interpretation solutions at Precision Medicine World Conference 2019 in
Silicon Valley, on January 22nd, as part of the Clinical and
Research Tools Showcase.

The presentation will discuss the challenges faced by clinics in
interpreting large and complex data from WGS, and will describe how
LifeMap’s NGS Analysis & Interpretation platform, TGex, is used to
tackle these challenges. TGex leverages the GeneCards Knowledgebase and
its sophisticated big data analysis tools for knowledge-driven
interpretation.

LifeMap Sciences’ TGex is a leading provider of tertiary NGS analysis
and interpretation solutions for rare pediatric disorders. It is today
the clinical genetics solution of choice for top tier pediatric and
maternal hospitals in China, Hong Kong and Italy amongst others,
including Bambino Gesù, the largest pediatric research center in Italy,
and top tier pediatric hospitals in China and Hong Kong. LifeMap also
provides TGex to leading sequencing companies such as Novogene Tianjin
Medical Laboratory in China.

The presentation will also include a live demonstration of WGS analysis
and interpretation using TGex and the GeneCards Knowledgebase, on
various cohorts of patients such as rare genetic disorders and cancer
predisposition, including analysis of structural variations and
regulatory elements.

LifeMap will also be exhibiting in Booth #506 at PMWC.

For inquiries, or for scheduling of private demonstrations of TGex and
the GeneCards Suite’s NGS interpretation solutions, please contact Yaron
Guan-Golan, CEO of LifeMap Sciences, at yg@lifemapsc.com.

About LifeMap Sciences

LifeMap Sciences is a life sciences technology company that offers
integrated, streamlined solutions that empower life scientists worldwide
to conduct cutting-edge basic, clinical and applied biomedical research.
LifeMap’s products are used in more than 3,000 institutions including
academia, research hospitals, patent offices, and leading biopharma and
diagnostic companies. Operations worldwide are carried out from our
offices in California, Massachusetts, New Jersey, Tel Aviv, and Hong
Kong. LifeMap is a subsidiary of AgeX Therapeutics, Inc.

For more information, please visit http://www.lifemapsc.com/.

About AgeX Therapeutics

AgeX Therapeutics, Inc. is focused on developing and commercializing
innovative therapeutics for human aging. Its PureStem® and UniverCyte™
manufacturing and immunotolerance technologies are designed to work
together to generate highly defined, universal, allogeneic,
off-the-shelf pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical need.
AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular
progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells)
for Type II diabetes. AgeX’s revolutionary longevity platform named
induced Tissue Regeneration (iTR™) aims to unlock cellular immortality
and regenerative capacity to reverse age-related changes within tissues.
AGEX-iTR1547 is an iTR-based formulation in preclinical development.
HyStem® is AgeX’s delivery technology to stably engraft PureStem cell
therapies and slowly release iTR molecules in the body. AgeX is
aggressively developing its core product pipeline for use in the clinic
to extend human healthspan, and is seeking opportunities to form
licensing and partnership agreements around its broad IP estate and
proprietary technology platforms for non-core clinical applications.

For more information, please visit www.agexinc.com
or connect with the company on Twitter, Facebook and YouTube.

Forward-Looking Statements

Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of AgeX Therapeutics, Inc. and
its subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in the “Risk Factors” section of AgeX’s
Information Statement filed as an exhibit to its Registration Statement
on Form 10 with the Securities and Exchange Commissions (copies of which
may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. AgeX specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.

Contacts

Bill Douglass
Gotham Communications, LLC
bill@gothamcomm.com
(646)
504-0890

QIAGEN N.V. to Report Fourth Quarter and Full Year 2018 Results

VENLO, The Netherlands–(BUSINESS WIRE)–QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) plans as
previously announced to release its report on results for the fourth
quarter 2018 on Monday, February 4 at approximately 22:05 Central
European Time (CET) / 16:05 Eastern Standard Time (EST). A
conference call is planned for Tuesday, February 5 at 15:00 CET /
9:00 EST hosted by Peer M. Schatz, Chief Executive Officer, and Roland
Sackers, Chief Financial Officer.

Conference Call and Webcast Details
The conference call will
begin at 15:00 CET / 9:00 EST on Tuesday February 5, 2019.

Interested parties may listen to the call by
dialing:

+1 646 828 8195 (U.S.), +44 (0)330 336 9401 (UK),
+49 (0)69 2222 10763 (Germany).
To avoid waiting time, please join
the event conference 5-10 minutes prior to the start time using
the following Passcode: 966935

The webcast will be accessible at:
https://globalmeet.webcasts.com/starthere.jsp?ei=1226934&tp_key=09db1d88ba

A conference call replay will be available by using the following link:
https://globalmeet.webcasts.com/starthere.jsp?ei=1226934&tp_key=09db1d88ba

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global
provider of Sample to Insight solutions that enable customers to gain
valuable molecular insights from samples containing the building blocks
of life. Our sample technologies isolate and process DNA, RNA and
proteins from blood, tissue and other materials. Assay technologies make
these biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in seamless
and cost-effective workflows. QIAGEN provides solutions to more than
500,000 customers around the world in Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food
safety), Pharma (pharma and biotech companies) and Academia (life
sciences research).

As of September 30, 2018, QIAGEN employed approximately 4,900 people in
over 35 locations worldwide.

Further information can be found at http://www.qiagen.com.

Contacts

John Gilardi
Vice President Corporate Communications and Investor
Relations
+49 2103 29 11711
+1 240 686 2222
Email: ir@qiagen.com

Dr. Sarah Fakih
Director Investor Relations
+49 2103 29 11457
Email:
ir@qiagen.com

Revance Announces Pricing of Public Offering of Common Stock

NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq:RVNC), a biotechnology company
developing next-generation neuromodulators for use in treating aesthetic
and therapeutic conditions (“Revance” or the “Company”), today announced
the pricing of an underwritten public offering of 5,882,353 shares of
its common stock at a price to the public of $17.00 per share. Revance
has granted the underwriters a 30-day option to purchase up to an
aggregate of additional 882,352 shares from the Company. The gross
proceeds to the Company from the offering, excluding any exercise by the
underwriters of their 30-day option to purchase additional shares, are
expected to be approximately $100 million before deducting underwriting
discounts and commissions and other estimated offering expenses payable
by the Company. The offering is expected to close on or about January
22, 2019, subject to customary closing conditions. The Company intends
to use the net proceeds received from its offering of common stock for
working capital and general corporate purposes, including clinical trial
and related expenses, research and development expenses, general and
administrative expenses, and capital investments.

Goldman Sachs & Co. LLC, Cowen and Piper Jaffray are acting as
book-running managers and Guggenheim Securities is acting as lead
manager.

The securities described above are being offered by Revance pursuant to
an automatic shelf registration statement previously filed with the
Securities and Exchange Commission on December 5, 2017. The offering
will be made only by means of a prospectus supplement. When available,
copies of the prospectus supplement and accompanying prospectus relating
to the proposed public offering may be obtained by contacting Goldman
Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY
10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com;
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, or
by emailing PostSaleManualRequests@broadridge.com;
or Piper Jaffray & Co., Attn: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924, or by
email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About Revance Therapeutics, Inc.

Revance is a clinical-stage biotechnology company focused on the
development, manufacturing, and commercialization of novel
neuromodulators for multiple aesthetic and therapeutic indications.
Revance is leveraging its proprietary portfolio of botulinum toxin type
A compounds, formulated with its patented and proprietary peptide
excipient technology, to address unmet needs in large and growing
neuromodulator markets.

“Revance Therapeutics” and the Revance logo are registered trademarks of
Revance Therapeutics, Inc.

Forward-Looking Statements

Certain of the statements made in this press release are forward
looking, such as those, among others, relating to Revance’s expectations
regarding the completion of the proposed public offering. Actual results
or developments may differ materially from those projected or implied in
these forward-looking statements. Factors that may cause such a
difference include, without limitation, risks and uncertainties related
to whether or not Revance will be able to raise capital through the sale
of shares of common stock, the final terms of the proposed offering,
market and other conditions, the satisfaction of customary closing
conditions related to the proposed public offering and the impact of
general economic, industry or political conditions in the United States
or internationally. There can be no assurance that Revance will be able
to complete the proposed public offering on the anticipated terms, or at
all. Revance will need to raise additional capital to fund its
operations and may be unable to raise capital when needed, which would
force Revance to delay, reduce or eliminate its product development
programs or commercialization efforts. You should not place undue
reliance on these forward-looking statements, which apply only as of the
date of this press release. Additional risks and uncertainties relating
to the proposed offering, Revance and its business can be found under
the heading “Risk Factors” in the prospectus supplement (and documents
incorporated by reference therein) related to the proposed public
offering filed with the Securities and Exchange Commission. Revance
expressly disclaims any obligation or undertaking to release publicly
any updates or revisions to any forward-looking statements contained
herein to reflect any change in its expectations with regard thereto or
any change in events, conditions or circumstances on which any such
statements are based.

Contacts

INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert,
714-325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
John Grimaldi, 212-213-0006
jgrimaldi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

Proteus Digital Health® Launches Digital Oncology Medicines to Improve Patient Outcomes

Proteus, Fairview Health Services, and University of Minnesota Health
are First to Provide Digital Medicines to Cancer Patients

REDWOOD CITY, Calif. & MINNEAPOLIS–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/GI19?src=hash” target=”_blank”gt;#GI19lt;/agt;–Proteus
Digital Health®,
Inc., Fairview
Health Services
, and University
of Minnesota Health
announced today that for the first time cancer
patients are using digital oncology medicines to support treatment
regimens and improve outcomes. This advancement helps patients complete
oral chemotherapy cycles while oncologists gain new insights into their
patients’ treatment progress and overall health status. Proteus,
Fairview, and University of Minnesota Health unveiled the care model for
digital oncology medicines and a collaboration with the University of
Minnesota, at the ASCO-GI 2019 Gastrointestinal Cancers Symposium in San
Francisco.

Proteus developed the care model for oral digital oncology medicines
with University of Minnesota Health and Fairview, which is the first
health system in the world to prescribe digital capecitabine, a common
chemotherapy drug prescribed with the Proteus ingestible sensor.
Currently it is being used to help treat stage 3 and 4 colorectal cancer
patients.

“Proteus has given us a great opportunity to take our passion for better
care management of patients receiving oral oncolytics and move that
forward,” said University of Minnesota Physicians
oncologist/hematologist Dr. Edward Greeno, who also directs the
University of Minnesota Health oncology service line. “Proteus’ digital
medicine technology provides a more direct connection to the patient. It
creates a way for us to achieve a lot of things that happen when a
patient is in the clinic for infusions without them coming in person.
Also, we can gain insights about the patient that we can’t learn from an
office visit, like how the patient is doing with their treatment regimen
while at home, on a daily basis.”

The digital medicines program helps optimize treatment regimens while
maintaining a patient’s privacy. The program securely captures, records,
and shares information about the time, dose, and type of oral
chemotherapy medication taken. This information, as well as data on
rest, activity, and resting heart rate, can be shared with the patient’s
consent with their physician, pharmacist, or caretaker. The information
can only be seen by the patient and their designated individuals on a
secure, mobile-friendly platform developed by Proteus.

“Currently, providers make decisions about oral chemotherapy based on
patients’ best knowledge of their medication taking,” said Andrew
Thompson, CEO and Co-founder of Proteus Digital Health. “For the first
time, digital oncology medicines give providers and caregivers new
insights and ability to engage with more specific information in the
remote care of colorectal cancer patients. Based on our data around the
use of digital medicines in other treatment areas, we believe this will
enable oncology patients to stay on their therapy longer, avoid hospital
admissions, and have better response to therapy overall.”

To expand from its established base of cardiometabolic and infectious
disease expertise into oncology, Proteus partnered with Fairview
Ventures, the innovation arm of Fairview. Experts from one of the
nation’s leading oncology medication management programs at Fairview
Pharmacy Services and from the University of Minnesota Health oncology
service line formed the comprehensive team that developed the user
experience and workflows for digital medicines in the treatment of
colorectal cancer.

“Given the costs, complexity, and toxicity risk for oral chemotherapy,
digital oncology medicine is an exciting step forward in cancer care,”
says Paul Morales, PharmD, BCOP, Fairview Infusion Pharmacy manager at
the University of Minnesota Health Clinics and Surgery Center. “For
pharmacists, it helps us identify patients who might be struggling to
take their medication correctly and intervene, for example by giving
them a call to explain how to safely move forward if they do miss a
dose. For patients, it helps them feel in control as they take a more
active role in managing their medication. The results are better
outcomes for patients.”

To gather more real-world experience and data from cancer patients using
digital medicines, Proteus is launching a digital oral oncolytic
medication registry. This study will gather data from multiple sites
spanning academic medical centers to community practices and urban to
rural facilities. Patients from participating sites will be prescribed
digital capecitabine to assist them in their treatment. Data collected
from the study will be used to share best practices across many sites,
enabling richer data and outcome analysis.

“Proteus’ expansion of support for digital medicines into the oncology
treatment area is not only important for patients and providers, it will
be a game changer for the industry developing therapies intended to one
day eradicate cancer,” said Olivia Ware, Proteus’ new Senior Vice
President of US Markets and Franchise Development, who brings more than
15 years of commercial oncology experience from across a number of
biopharma companies. Data gathered from digital oral oncolytics will
enable cancer drugs and treatment regimens to be optimized to work their
best for each individual patient, something not possible until now.”

About Proteus Digital Health®

Proteus Digital Health is enabling a new category of pharmaceuticals:
Digital Medicines. These include widely used drugs, formulated so they
communicate when they have been ingested; a wearable patch that detects
medicines and captures physiologic response; mobile applications to
support patient self-care and physician decision-making; and data
analytics to serve the needs of health system managers. The company has
more than 540 issued patents that protect this enabling technology, and
regulatory clearances in the U.S., European Union and China.

Proteus Digital Health is privately held by investors that include
Carlyle, Essex Woodlands, Kaiser Permanente®, Medtronic®,
Novartis®, Otsuka, and ON Semiconductor®. Further
information is available at: www.proteus.com.
Connect with us on Twitter @ProteusDH.

About Fairview Health Services

Fairview Health Services (fairview.org)
is a Minneapolis-based nonprofit health system driven to heal, discover
and educate for longer, healthier lives. Founded in 1906, Fairview
provides exceptional care to patients and communities as one of the most
comprehensive and geographically accessible systems in Minnesota.
Fairview has enjoyed a long partnership with the University of Minnesota
and University of Minnesota Physicians, which is represented in the
University of Minnesota Health brand. Together, we offer access to
breakthrough medical research and specialty expertise as part of a
continuum of care that reaches all ages and health needs. In 2018, we
extended our partnership, with work underway to build an academic health
system focused on patient-centered care, innovation, and clinical
excellence.

About University of Minnesota Health

University of Minnesota Health represents a collaboration between
University of Minnesota Physicians and University of Minnesota Medical
Center. Working together, we provide exceptional care in a wide range of
specialties at our hospitals, clinics and in community-based facilities
throughout the region. Visit: www.mhealth.org.

Contacts

Emily Fox, Director of Communications
Proteus Digital Health, Inc.
Tel:
+1 650.637.6240
Email: efox@proteus.com

Krystle Barbour, Media Relations Manager
Office of Communications –
Medical School
University of Minnesota | med.umn.edu
Office:
612-626-2767
Email: kbarbour@umn.edu

Hardman & Co Research: Allergy Therapeutics (AGY): Trading update: gaining market share

Hardman & Co Research

17-Jan-2019 / 09:56 GMT/BST


Hardman & Co: Trading update: gaining market share

AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. The Pollinex Quattro (PQ) platform, the ultra-short course subcutaneous allergy immunotherapy (AIT), continues to gain market share, despite its availability in the EU only on a ‘named-patient’ basis. 2019 is expected to deliver progress in several areas, notably PQ Birch, for which top-line Phase III data are due in 1Q’19. A trading update has confirmed strong market share gains and cash generation in the traditionally strong 1H period. AGY also has important meetings scheduled with both the EU and US regulators during 1Q’19 regarding PQ grass trials. Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/trading-update-gaining-market-share/

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo

Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622

mh@hardmanandco.com
dmh@hardmanandco.com
gp@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

Hardman & Co Research: 1pm Plc (OPM): Interim results 1H FY’19: geared up for growth

Hardman & Co Research

16-Jan-2019 / 09:51 GMT/BST


Hardman & Co Research: Interim results 1H FY’19: geared up for growth

We had been looking for two key themes with the 1H FY’19 results: i) that any early signs of credit deterioration were modest; and ii) that the integrations were going well. 1pm delivered on both. On credit, the net bad debt write-off was down on last year. Management detailed the diversification of the business, and commented how its operating flexibility, small individual exposures, human underwriting and fixed-rate lending should limit losses in a downturn. On group synergies, we note cross referrals are ticking up each month and the cost of group funds is falling. 1H FY’19 saw good franchise and revenue growth. The valuation appears anomalous with the group’s prospects.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/interim-results-1h-fy19-geared-up-for-growth/

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo

Contact:

Mark Thomas

+44 20 7194 7622

mt@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

Terns Pharmaceuticals Announces the Appointment of Erin Quirk, M.D., as Chief Medical Officer

SAN MATEO, Calif. & SHANGHAI–(BUSINESS WIRE)–Terns Pharmaceuticals Inc., a global biopharmaceutical company focused
on discovering and developing molecularly targeted, oral, small-molecule
drugs to treat NASH and cancer, announced today the appointment of Erin
Quirk, M.D. as Chief Medical Officer (CMO). Dr. Quirk brings more than
two decades of clinical medicine and drug development experience, most
recently serving as Vice President of Clinical Research at Gilead
Sciences.

“Erin is a highly accomplished clinician with an extensive track record
in developing and registering new treatments for infectious diseases and
liver diseases. Her expertise will be invaluable as we advance our
portfolio of NASH drugs, including TERN-101, TERN-201, and future
pipeline candidates, through the clinic,” said Weidong Zhong, Ph.D.,
President and CEO of Terns. “We are delighted to have Erin join us at
this critical time in our company’s growth, as her proven leadership and
background in both early and late-stage drug development make her well
suited to lead the growing Terns clinical development team.”

Dr. Quirk commented, “I am excited to be a part of this dedicated team
focused on developing treatments for NASH, which currently has no
approved treatments. I look forward to leveraging my clinical
development background to advance these important drug candidates.”

Previously Dr. Quirk was Vice President, Clinical Research at Gilead
Sciences where she oversaw all phases of clinical development for
Gilead’s HIV treatment, prevention and cure franchise and was
responsible for strategy and life-cycle maintenance for the company’s
HIV portfolio, advancing multiple compounds and combination products
into clinical development and through the approval process. She also led
the clinical development of small molecules within Gilead’s emerging and
neglected viral diseases portfolio, including antivirals for Ebola virus
disease. Prior to joining Gilead, Dr. Quirk was Director of Clinical
Research at Merck where she advanced clinical trials for Merck’s
investigational HIV vaccine products and oversaw the clinical
development of small molecules for hepatitis C virus infection. Dr.
Quirk holds an MD from the University of Colorado and completed training
in internal medicine and infectious diseases at Washington University in
St. Louis where she was a faculty member prior to joining the
pharmaceutical industry.

About Terns Pharmaceuticals

Based in San Mateo, CA., and Shanghai, China, Terns Pharmaceuticals is a
global biopharmaceutical company committed to discovering and developing
molecularly targeted, oral, small molecule drugs to treat liver disease
and cancer. The company combines expertise in disease biology, medicinal
chemistry and extensive clinical development capabilities in China to
advance its growing pipeline of drugs that are optimized against
clinically validated targets or targets that have significant
preclinical validation. Using a capital-efficient drug discovery model,
the company’s mission is to bring promising new therapies to patients in
underserved markets via global and region-specific development programs.
Terns plans to focus initial development activities on regulatory
approval in China and explore clinical development in additional global
markets. For more information, visit www.TernsPharma.com.

Contacts

US Media Contact:
Margaret Robinson
+(415)-690-0084

China Media Contact:
Eddy Wu
+ 86 180 1631 1449